NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting February 18, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by globenewswire. Read more Source: https://www.globenewswire.com/news-release/2026/02/17/3239083/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-Path-to-New-Drug-Application-with-Real-World-Data-and-Broader-Proposed-Indication-for-NRX-100-ketamine-Following-Type-C-FDA-Meeting.html
